LOW-NICKEL DIET AS A STRATEGY IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION
- PMID: 40699043
- PMCID: PMC12289288
- DOI: 10.1590/S0004-2803.24612024-108
LOW-NICKEL DIET AS A STRATEGY IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION
Abstract
Context: The rising antibiotic resistance in Helicobacter pylori (H. pylori) infection have made treatment more challenging. A low-nickel diet may improve eradication rates based on the bacteria's mechanisms.
Objective: This study aimed to evaluate the effect of a low-nickel diet during standard triple therapy on the rate of H. pylori eradication.
Methods: This randomized clinical trial included patients with H. pylori infection who were classified into the following two groups: low-nickel diet and regular diet. Both groups received the standard triple therapy with amoxicillin, clarithromycin, and a proton pump inhibitor. After at least 8 weeks of treatment, a control test for H. pylori was performed.
Results: Per-protocol analysis showed a higher rate of H. pylori eradication in the low-nickel diet group than in the regular diet group (91.7% vs 75.8%; P=0.026). In addition, obesity was associated with poorer eradication rates (73.2% vs 88.9%, P=0.038). Patients on a low-nickel diet were 3.41 times (1.21-11.40) more likely to have H. pylori eradication than those on a normal diet.
Conclusion: This study showed that low-nickel diet, which is a low-cost and low-risk intervention, may be an appropriate strategy for increasing H. pylori eradication rates.
Background: • Evaluate the effect of low-nickel diet during standard triple therapy on the rate of Helicobacter pylori eradication.
Background: • This randomized clinical trial included patients infected with Helicobacter pylori in groups with a low-nickel nickel or regular diet, who underwent standard triple therapy and the efficacy of bacterial eradication was compared between both groups.
Background: • Per-protocol analysis showed a higher rate of Helicobacter pylori eradication in the low-nickel diet group than in the regular diet group (91.7% vs 75.8%; P=0.026).
Background: • The low-nickel diet is an appropriate strategy for increasing Helicobacter pylori eradication rates.
Contexto:: O aumento das taxas de resistência aos antibióticos na infecção por Helicobacter pylori (H. pylori) tem tornado o tratamento desafiador. Uma dieta pobre em níquel pode melhorar as taxas de erradicação com base nos mecanismos da bactéria.
Objetivo:: Este estudo teve como objetivo avaliar o efeito de uma dieta pobre em níquel durante a terapia tripla padrão nas taxas de erradicação do H. pylori.
Métodos:: Este ensaio clínico randomizado incluiu pacientes com infecção por H. pylori, classificando-os em dois grupos: dieta pobre em níquel e dieta padrão. Ambos os grupos receberam terapia tripla padrão com amoxicilina, claritromicina e um inibidor da bomba de prótons. Um exame de controle de cura do H. pylori foi realizado após pelo menos 8 semanas do tratamento.
Resultados:: A análise por protocolo revelou uma taxa de erradicação mais alta no grupo da dieta pobre em níquel em comparação ao grupo da dieta padrão (91,7% vs 75,8%; P=0,026). Além disso, a obesidade estava associada a taxas de erradicação mais baixas (73,2% vs 88,9%; P=0,038). Pacientes em uma dieta pobre em níquel tinham 3,41 vezes mais chances (1,21-11,40) de erradicação do H. pylori em comparação aos que estavam em uma dieta padrão.
Conclusão:: Este estudo sugere que uma dieta pobre em níquel, intervenção econômica e de baixo risco, pode aumentar as taxas de erradicação do H. pylori.
Conflict of interest statement
Figures


Similar articles
-
Sequential versus standard triple first-line therapy for Helicobacter pylori eradication.Cochrane Database Syst Rev. 2016 Jun 28;2016(6):CD009034. doi: 10.1002/14651858.CD009034.pub2. Cochrane Database Syst Rev. 2016. PMID: 27351542 Free PMC article.
-
Optimum duration of regimens for Helicobacter pylori eradication.Cochrane Database Syst Rev. 2013 Dec 11;2013(12):CD008337. doi: 10.1002/14651858.CD008337.pub2. Cochrane Database Syst Rev. 2013. PMID: 24338763 Free PMC article.
-
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence.Drugs. 2013 Jun;73(8):815-24. doi: 10.1007/s40265-013-0053-z. Drugs. 2013. PMID: 23625272
-
Efficacy and safety of triple therapy with vonoprazan for Helicobacter pylori eradication: A multicenter, prospective, randomized controlled trial.World J Gastroenterol. 2025 Jul 28;31(28):109001. doi: 10.3748/wjg.v31.i28.109001. World J Gastroenterol. 2025. PMID: 40741473 Free PMC article. Clinical Trial.
-
Effects of amoxicillin dosage on cure rate, gut microbiota, and antibiotic resistome in vonoprazan and amoxicillin dual therapy for Helicobacter pylori: a multicentre, open-label, non-inferiority randomised controlled trial.Lancet Microbe. 2025 Mar;6(3):100975. doi: 10.1016/j.lanmic.2024.100975. Epub 2024 Dec 18. Lancet Microbe. 2025. PMID: 39708826 Clinical Trial.
References
-
- Coelho LGV, Marinho JR, Genta R, Ribeiro LT, Passos M do CF, Zaterka S, et al. IVth Brazilian consensus conference on Helicobacter pylori infection. Arq Gastroenterol. 2018;55:97–121. - PubMed
-
- Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71:1724–1762.
-
- Felga G, Silva FM, Correa Barbuti R, Navarro-Rodriguez T, Zaterka S, Eisig JN. Clarithromycin-based triple therapy for Helicobacter pylori treatment in peptic ulcer patients. J Infect Dev Ctries. 2010;4:712–716. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical